[Treatment of acute and chronic urological infections with azlocillin--clinical and microbiological research].

The authors present their results from the treatment of urological infections with the new semisynthetic penicillin antibiotic azlocillin (acyl-ureide-penicillin) in 86 patients with various, in kind and clinical manifestations, infections of the urinary system. The susceptibility was determined of the isolated bacterial causative agents of the urological infections to azlocillin and to the other antibacterial preparations available in our country. It was established that 52,7% of Gram-negative microorganisms were susceptible to the preparation, and over 80%--of the Gram-positive microorganisms. The highest number of susceptible strains were established in pseudomonas, coli, enterobacter, klebsiella and proteus. The results from the clinical study reveal that 51,2% of the patients were cured by the end of the therapeutic course and abatement or considerable improvement, was observed in all, of the clinical and paraclinical indices, suggesting urological infection. No allergic or toxic manifestations were observed. The absence of nephrotoxicity makes that new, for our practice, antibiotic extremely valuable for the patients with renal insufficiency. The most general conclusion from that study is that azlocillin, with its effectiveness, comes close to the most potent modern antibacterial preparations, with no toxicity characteristic for aminoglucoside antibiotics.